Fund in Focus: George Putnam Fund of Boston
Jeanne L. Mockard, lead manager since April 2000 S&P Rank: 3 Stars Venerable Fund Sticks To Its Knitting
Richard Cervone of Putnam Tax-Smart Equity Fund
S&P Rank: 5 Stars Tax-Aware Fund Seeks Good Fundamentals First
Mark Mulholland of Matthew 25 Fund
S&P Rank: 5 Stars Keeping His Investment Lamp Trimmed
John C. Thompson of Thompson Plumb Growth Fund
S&P Rank: 5 Stars Growth, By Any Other Name
Fund in Focus: Smith Barney Fundamental Value Fund
July 16, 2004 -- The Smith Barney Fundamental Value/A (SHFVX) began buying large pharmaceuticals companies late last year. At that time, their stocks were trading...
Fund in Focus: Evergreen Strategic Growth Fund
Jay Zelko, co-manager since April 2000 S&P Rank: Not Ranked. Best Expectations
Durus Settles, Pays Esperion $32 Million
ANN ARBOR, Mich. (HedgeWorld.com)--Esperion Therapeutics Inc., settled its civil lawsuit against Durus Life Sciences Master Fund Ltd., three weeks after Esperion agreed to be acquired...
Liu-Er Chen of Evergreen Health Care Fund
S&P Rank: 4 Stars Aug. 14, 2003 On the Cusp of a New Drug Boom Quick Take: Drug and biotech stocks suffered in 2002, hurt by poor earnings,...
Evan McCulloch of Franklin Biotechnology Discovery
S&P Rank: 3 Stars Strong Dose of Biotech
Michael Yellen of AIM Global Health Care Fund
S&P Rank: 4 Stars Good Prognoses for Drug Stocks